Abstract
It gives me enormous pleasure to welcome you to the newly rebranded and renamed Clinical OMICs. As we enter a new chapter in the magazines' evolution, I want to thank my predecessor Chris Anderson for his stewardship and his steady hand on the tiller in steering the narrative over recent years. I am enthused and energised by the immediate and longer term plans we have for IPM, as we aim to position ourselves as the eyes and ears ‘inside' the industry. We'll take an expansive view of the some of the misalignments and quotidien challenges that exist across the healthcare spectrum and I pledge that we will become the mouthpiece for all voices, especially those of patients, as they help drive this revolution, as active participants in the dialogue.
This relaunch issue focuses principally on AI and how it is able to predict early warning signs across many chronic diseases, in some cases, extrapolating the value buried deep in unstructured data, to build a true picture of predisposition and indeed progression of disease. Precision medicine can only flourish if it is extracting the right data and AI will continue to be its strongest ally as we continue to understand the relationship between genotype and phenotype.
So, as we progress this year with our renewed brand identity, we intend to capture the stories behind the stories, disseminating engaging news and opinions through multiple and diverse lenses. We are brimming with ideas that we plan to bring to fruition, not only in print but through our digital platforms as well. I aim to take this privileged baton and continue this foundational work, encouraging robust reporting of the critical issues that matter, whilst maintaining a wide aperture across a very complex and diverse landscape. I hope this newly designed issue enhances your reading experience and stimulates ideas of your own that you may wish to suggest as contributions for future issues.
Damian Doherty, Editor in Chief
